Compare Ascendis Pharma A/S (ASND) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Paychex, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.09 (market cap $16.67B), while Paychex, Inc. trades at $119.3 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 2.6× Ascendis Pharma A/S's market cap, and Paychex, Inc. pays a 3.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PAYX | |
|---|---|---|
Market Cap | $16.67B | $43.14B |
Sector | Health | Industrials |
52-Week High | $277.18 | $140.81 |
52-Week Low | $189.74 | $85.57 |
Enterprise Value | $17.04B | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Paychex (PAYX) trades at $121.18, up 0.95% with a bullish technical outlook and strong fundamentals. The company maintains robust profitability with 27.03% net margins and consistent earnings beats. Recent expansion of WISE platform and steady small business employment trends support growth. Technical indicators show bullish momentum with support at $120 and resistance at $122.
PAYX offers stable dividend income and consistent execution but faces valuation concerns with P/E of 24.81 above sector averages. Analyst consensus remains cautious with 63% hold ratings. Key risks include economic sensitivity and competitive pressures in HR services. Upside depends on continued market share gains and margin maintenance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
